The rapid expansion of global pharmaceutical supply chains has placed unprecedented pressure on logistics systems to deliver certainty at every step. As therapies become more temperature-sensitive, more personalised and more regulated, the reliability of transport networks increasingly determines not only commercial outcomes but clinical ones.
In a sector where delays can compromise product stability and patient safety, air cargo has assumed a pivotal role in ensuring that medicines cross borders with speed, precision and regulatory integrity. Industry leaders examining this shift argue that air logistics is no longer simply a mode of transport, but it is a strategic instrument that underpins the viability of modern healthcare delivery.
This growing centrality of air freight reflects a structural change in the pharmaceutical landscape. Biologics, vaccines, high-value injectables and cell- and gene-based therapies demand controlled environments, continuous monitoring and fully traceable chain-of-custody processes.
Ocean and ground transport remain integral to global distribution, but they cannot provide the immediacy or the risk tolerance required for high-stakes medical consignments. As a result, the air cargo sector is being pushed to evolve into a more sophisticated, standardised and digitally governed ecosystem.
Airports as pharma-ready ecosystems
Airports sit at the core of this ecosystem, yet many are still grappling with the requirements of pharmaceutical cargo. Suresh Nair, Head of Cargo at Navi Mumbai International Airport, emphasised that the sector is entering an era in which infrastructure must be designed specifically for pharma flows, not adapted after the fact. “Air cargo infrastructure must evolve to match the precision and accountability required by pharmaceutical supply chains,” he said.
Nair argued that future-ready airports will need integrated temperature-controlled environments, rapid cross-docking capabilities and automated exception-management tools embedded into everyday operations.
He noted that “airports will increasingly be judged not on capacity alone but on their ability to maintain validated conditions from aircraft arrival to landside dispatch.” The complexity of pharma logistics, he added, requires collective operational discipline across handlers, carriers, regulators and technology providers.
Certified corridors and the economics of predictability
For freight forwarders, the pharmaceutical market presents a unique reliance on predictability, whether in handling, documentation or uplift availability. Aseem Kapoor, Country Head, Air Freight, stressed that certified pharma corridors, rather than ad hoc routing decisions, now underpin the credibility of the entire distribution model. “Pharma logistics cannot tolerate variability,” he observed, noting that consistency in temperature control, documentation standards and handling processes is crucial for risk mitigation.
Kapoor argued that airlines must reinforce operational planning for high-dependency lanes, with structured winter programmes, guaranteed capacity allocations and proactive intervention protocols. These measures, he explained, “ensure that a product remains in a validated state throughout its journey.”
He emphasised that the cost of non-compliance far exceeds the incremental expense of building certified lanes.
Raising the bar: The global standardisation of pharma air cargo
Sitting at the intersection of regulatory oversight and commercial service delivery, airlines are facing intensifying expectations for quality assurance. Steffani Souza, Global Head of Pharma Product at Delta Cargo, described a sector undergoing rapid professionalisation. “Pharma is no longer a niche vertical, it’s a global discipline with its own architecture of standards,” she said.
Souza highlighted the increasing alignment around frameworks such as GDP and CEIV, noting that certification must move beyond a compliance milestone to become a continuous operational practice embedded into training, audit cycles and real-time decision-making.
Souza further stressed the importance of digital continuity, explaining that regulators and shippers now expect carriers to provide credible, tamper-proof visibility from origin to destination. For airlines, she added, “the challenge lies not only in physical handling but in delivering a digital chain of custody that can withstand regulatory scrutiny.”
Logistics as a clinical variable
For pharmaceutical manufacturers, supply chain risk is intimately tied to therapeutic outcomes. Dr Arloph John Vieira, Vice President, Supply Chain at Bajaj Healthcare, argued that logistics is now considered a determinant of product integrity rather than a downstream operational step. “When a delay jeopardises the stability of a product, the impact is clinical, not operational,” he said.
Vieira noted that manufacturers increasingly calibrate production scheduling, batch release strategies and regulatory filings based on the reliability of logistics networks. He highlighted that, “growing pressure to validate alternate routes and contingency lanes is an approach only feasible when air corridors offer standardised handling practices and robust documentation.”
In Vieira’s view, the implication is clear that logistics failures can translate into product recalls, regulatory setbacks and compromised patient care.
Digital accountability and the rise of predictive risk tools
Amritendu Mukherjee, Head of Global Logistics at Dr Reddy’s Laboratories, underscored that visibility platforms must extend well beyond temperature readings. “Digital compliance is now a determinant of lane viability,” he explained, calling for systems capable of predictive alerts, chain-of-custody authentication, automated documentation checks and integrated regulatory reporting.
Mukherjee stressed that predictive modelling will play an increasing role in planning for uplift disruptions, adverse weather patterns and congestion at major hubs.
For him, the shift towards data-driven logistics reflects a deeper truth that, in the pharma sector, time lost is not merely a commercial delay but a potential clinical risk and digital transparency is becoming an essential prerequisite for pharmaceutical logistics.
A new logistics architecture – evolving pharma landscape
Senior industry leader, Keku Bomi Gazder, MD & CEO of Aviapro Logistic Services, steered the discussion by highlighting three pillars that will define the sector’s future, which are certified infrastructure, digital governance and cross-industry standardisation.
As therapies become more sensitive and regulatory expectations tighten, he noted, air cargo will remain central to ensuring continuity of care. The broader conclusions are unmistakable. Pharmaceutical logistics is entering a new phase characterized by uncompromising expectations for certainty, end-to-end traceability and precision handling.
Air cargo’s role has expanded far beyond transportation; it is now a guarantor of product viability and patient safety. To meet this challenge, airports, airlines, forwarders and manufacturers must operate within a unified, evidence-driven system where accountability is continuous and failure is not an option.
As India and other global manufacturing hubs scale their pharmaceutical output, the strength of their air logistics networks will increasingly shape their international competitiveness. In an industry defined by life-saving precision, the logistics architecture must display the same discipline and scientific rigour as the medicines it carries.
The post How air cargo is becoming the strategic backbone of global pharmaceutical logistics appeared first on Air Cargo Week.
Go to Source
Author: Ajinkya Gurav
